Payer perspectives on genomic testing in the United States: A systematic literature review Read more about Payer perspectives on genomic testing in the United States: A systematic literature review
Research for all: Building a diverse researcher community for the All of Us Research Program Read more about Research for all: Building a diverse researcher community for the All of Us Research Program
Nephrologists' views on a workflow for returning genetic results to research participants Read more about Nephrologists' views on a workflow for returning genetic results to research participants
Applications and concerns of ChatGPT and other conversational large language models in health care: Systematic review Read more about Applications and concerns of ChatGPT and other conversational large language models in health care: Systematic review
Ethical, legal, and social issues related to genetics and genomics in cancer: A scoping review and narrative synthesis Read more about Ethical, legal, and social issues related to genetics and genomics in cancer: A scoping review and narrative synthesis
Genomics research in Africa and its impact on global health: Insights from African researchers Read more about Genomics research in Africa and its impact on global health: Insights from African researchers
Artificial intelligence, medications, pharmacogenomics, and ethics Read more about Artificial intelligence, medications, pharmacogenomics, and ethics
Ethical and legal reflections on secondary research using genetic data acquired for criminal investigation purposes Read more about Ethical and legal reflections on secondary research using genetic data acquired for criminal investigation purposes
Ready, set, sort! A user-guide to card sorts for community-engaged empirical bioethics Read more about Ready, set, sort! A user-guide to card sorts for community-engaged empirical bioethics
Financial impacts of paying for gene therapy for sickle cell disease under alternate prices and financing mechanisms Read more about Financial impacts of paying for gene therapy for sickle cell disease under alternate prices and financing mechanisms
